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Purpose: Treatment adherence is a prerequisite for treatment success and therefore an important 
consideration to assure that therapeutic goals are achieved both from a patient point of view 
and for optimal health care resource utilization. Published data on treatment adherence with 
fingolimod (Gilenya®) are limited. Therefore, this study investigated treatment adherence in 
patients with relapsing-remitting multiple sclerosis (RRMS) treated with fingolimod in Denmark.
Patients and methods: This was a 24-month, multicenter, open-label study, investigating 
treatment adherence, satisfaction, motivation, and health-related quality of life (QoL) in RRMS 
patients treated with fingolimod. In addition, the effect of a motivational interview support pro-
gram on these measures was evaluated. Treatment adherence was assessed by pill count. Treat-
ment satisfaction, motivation, and QoL were assessed by patient-reported outcomes (PROs).
Results: A total of 195 patients were enrolled in the study. A very high treatment adherence 
was observed during the entire study with no statistically significant difference between study 
visits before (99%) and after (97%) the motivational interview. In accordance, a high level of 
treatment satisfaction was found in the Treatment Satisfaction Questionnaire for Medication 9, 
which was scored high throughout the study with the highest scores seen for the convenience 
domain (ranging from 94.51 to 95.78). Furthermore, additional PROs demonstrated a high 
health-related QoL, a self-determined form of motivation for taking medication, and a patient 
perception of an autonomy supportive approach provided by the health care provider, at all 
study visits.
Conclusion: High levels of treatment adherence, satisfaction, motivation, and QoL were 
observed in Danish RRMS patients treated with fingolimod. As these positive measures were 
observed at all study visits and throughout the study, no effect of the motivational interview 
support program was found.
Keywords: Gilenya®, multiple sclerosis, treatment adherence, motivational interview, quality 
of life, Treatment Satisfaction Questionnaire for Medication
Introduction
Multiple sclerosis (MS) is a chronic, autoimmune demyelinating disease of the central 
nervous system (CNS) affecting more than 2.3 million people worldwide.1,2 The 
disease targets the myelin sheaths around nerves, leading to inflammation, myelin 
loss, and axonal destruction leading to disability. The most common form of MS, 
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affecting around 85% of MS patients, is relapsing-remitting 
MS (RRMS), which is characterized by episodes of relapse 
followed by periods of remission. RRMS often develops into 
secondary progressive MS, where the symptoms gradually 
worsen and accumulate without a relapsing nature.3
Symptoms of MS vary in type and severity between 
patients and even within the same patient. Common symp-
toms include fatigue, visual disturbances, altered sensation, 
depression, numbness, weakness, bladder and bowel dysfunc-
tion, sleep disorders, cognitive impairment, and difficulties 
with mobility.1 Importantly, the disabling nature of the 
disease significantly impairs the quality of life (QoL) of the 
patients by interfering with their daily activities.4
Although MS is currently incurable, long-term treatment 
with disease-modifying therapies (DMTs) has been shown to 
reduce relapse rates and thus the risk of disability progression 
in RRMS. A broad panel of DMTs with different modes and 
frequencies of administration is available including different 
injectable, oral, and intravenous therapies.5
Poor adherence to long-term therapy for chronic illnesses, 
including MS, is a common problem.6,7 According to the 
World Health Organization (WHO), adherence among 
patients suffering from chronic diseases is as low as 50% in 
developed countries and probably even lower in developing 
countries.6 Specifically, for MS, rates of adherence to DMTs 
have been reported to range from as low as 28% up to 88%.8 
Numerous factors contribute to this non-adherence in MS, 
for example, cognitive impairment and depression, fear of 
medicine administration and inconvenience of use, side 
effects, and insufficient caregiver support.7,9
For chronic diseases such as MS, administration of 
DMT as prescribed is a prerequisite for treatment success. 
In this regard, several studies have shown that adherent 
patients tend to have a lower risk of relapses, lower risk of 
hospital admission, fewer emergency visits, and fewer visits 
to their physician compared to nonadherent patients.10,11 
Thus, adherence to a specific medication regimen is an 
important consideration to assure that therapeutic goals are 
achieved both from a patient point of view and considering 
health economy in terms of optimal health care resource 
utilization.
Fingolimod (Gilenya®; Novartis International AG, Basel, 
Switzerland) was the first oral, once daily DMT to gain 
regulatory approval for the treatment of RRMS. Fingolimod 
is a sphingosine-1-phosphate receptor modulator.12 The 
active metabolite fingolimod phosphate blocks the migra-
tion of lymphocytes from lymph nodes, thereby reducing 
the number of lymphocytes in peripheral blood, and hence 
reduces lymphocyte migration into the CNS. Fingolimod has 
demonstrated clinical efficacy in reducing relapses, delaying 
disability progression, and improving MRI and brain volume 
loss outcomes in phase 3 clinical trials.13
Given that adherence is key to the effectiveness of DMTs, 
a thorough understanding of adherence and medication-
taking behavior to individual DMTs is paramount for 
optimal patient care and health care utilization. Published 
data on treatment adherence in RRMS patients treated 
with fingolimod are limited. This also applies to the level of 
treatment satisfaction, motivation, and QoL in these patients, 
all of which are important determinants for adherence to treat-
ment. The present 24-month, multicenter, open-label study 
therefore investigated the adherence, treatment satisfaction, 
motivation, and health-related QoL in RRMS patients treated 
with fingolimod. In addition, the effect of a motivational 
interview support program including motivational interview 
training of the participating investigators on these measures 
was evaluated as was the safety of the treatment.
Patients and methods
study design
This was a 24-month, multicenter, open-label study to inves-
tigate the treatment adherence, satisfaction, motivation, and 
QoL in RRMS patients treated with fingolimod. In addition, 
the effect of a motivational interview support program on 
these measures was evaluated. Patients were recruited from 
eight different MS clinics in Denmark. The patient database 
at each clinic served as the source of recruitment, thus all 
patients recruited had at least 6 months fingolimod treatment 
prior to enrollment in the study.
The study consisted of two phases: a 12-month observa-
tional run-in phase and a 12-month motivational interview 
phase where the effect of a motivational interview support 
program was evaluated (Figure 1). At the screening/baseline 
visit (visit 1), patients were evaluated for eligibility in the 
study, and if eligible, baseline assessments of treatment 
adherence, satisfaction, motivation, and health-related QoL 
were performed. After the screening/baseline visit, patients 
visited the clinic every 6 months (±1 month visit window) 
for post-baseline assessments of these parameters for a total 
study duration of 2 years.
The study was done in full accordance with Good Clinical 
Practice and the Declaration of Helsinki as adopted by the 
World Medical Association as well as Danish laws and 
regulations. Prior to conduct, the study was approved by both 
the National Committee on Health Research Ethics and the 
Danish data protection agency.
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Motivational interview training
Motivational interviews were performed at each visit to the 
clinic in the motivational interview phase (ie, from visit 3 
and onwards, Figure 1). Before the initiation of the moti-
vational interview phase, the participating study personnel 
were trained in motivational interviewing (between visits 2 
and 3 for all sites).
All health care professionals underwent a 2-day course 
in motivational interviewing techniques where they were 
trained in motivational interviewing by trainers who were 
certified members of the Motivational Interviewing Network. 
The effect of training was investigated by using Motivational 
Interviewing Treatment Integrity (MITI) coding 3.1.14 Addi-
tional booster trainings (2-hour sessions) were conducted 
locally at each clinic, 3–9 months after the initial training.
Motivational interviewing represents a specific method 
employed by the doctor to counsel their patients with the 
overall purpose of changing their behavior and increase the 
patients’ own motivation for a particular intervention, in this 
case intake of medication.15 The overall concept of motiva-
tional interviewing is for the doctors to create a supportive 
patient–doctor relationship rather than a compelling one. 
The technique may help the doctor with patients who are 
averse to behavioral changes, and it has been implemented 
successfully in several therapies.16
study population
All patients gave written informed consent before entering 
the study. Patients were eligible for inclusion if they were 
aged 18–55 years, were diagnosed with RRMS according to 
the 2005 revised McDonald criteria,17,18 and had an expanded 
disability status scale (EDSS) score between 0 and 6.5. 
To avoid misinterpretation of adherence due to, for example, 
low tolerance leading to change of treatment or high adherence 
during the first treatment period, patients were required to 
having received fingolimod for a minimum of 6 months prior 
to inclusion. Patients who had received systemic corticoster-
oids or immunoglobulins within 1 month prior to screening, 
immunosuppressive medications or monoclonal antibodies 
(including natalizumab; Biogen, Cambridge, MA, USA) 
within 3 months prior to screening, or mitoxantrone within 6 
months prior to screening were not eligible for the study.
study assessments
effect of motivational interview training of health 
care professionals
To assess the effect of motivational training of the health 
care professionals, MITI 3.1 scoring of the interviewers was 
performed before and after the training. In this regard, two 
independent educated trainers evaluated the implementation 
of motivational interviews at the study sites by scoring video 
records (15–20 min duration) of patient consultations taken 
before and after the motivational interview training.
Treatment adherence
Treatment adherence was assessed after 6, 12, 18, and 
24 months in the study (Figure 1) based on pill count. Patients 
were asked to bring all their study medication to the clinic at 
the screening/baseline visit (visit 1) and at all post-baseline 
visits to the clinic. Adherence was then calculated as number 
Figure 1 Overall study design.
Abbreviations: TsQM-9, Treatment satisfaction Questionnaire for Medication 9; TsrQ, Treatment self-regulation Questionnaire; hrQl, health-related quality of life; 
hccQ, health-care climate Questionnaire; Qol, quality of life; sF-12, 12-item short form questionnaire.
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of dispensed pills minus number of pills brought to the visit 
divided by the number of days between respective visits.
Treatment satisfaction
Treatment satisfaction was assessed after 6, 12, 18, and 
24 months in the study (Figure 1) by using the abbreviated 
Treatment Satisfaction Questionnaire for Medication 9 
(TSQM-9) score.19 The TSQM-9 assesses the overall level 
of satisfaction of patients with their treatment. It consists of 
nine questions focusing on the individual domains of effec-
tiveness, convenience, and global satisfaction. Domain scores 
range from 0 to 100 with higher TSQM scores indicating 
greater treatment satisfaction within a particular domain.
Patient satisfaction with their medication has been shown 
to impact treatment-related behavior, including their likeli-
hood of continuing to use their medication and to adhere to 
their treatment.20–22
Motivation
Controlled forms of motivation and amotivation have 
previously been linked to non-adherence to treatment.23,24 
Motivation was assessed after 6, 12, 18, and 24 months in 
the study (Figure 1) by using the Treatment Self-Regulation 
Questionnaire25 (TSRQ) and the Health-Care Climate 
Questionnaire (HCCQ).26
Patients’ self-motivation toward taking their medication 
was assessed with the TSRQ assessing the degree to which 
behaviors tend to be self-determined. The TSRQ used in the 
present study consisted of 15 questions with a range of 1–7 
and has been endorsed by the Behavior Change Consortium 
(BCC) investigators. The questionnaire has been validated 
across three different health behaviors (tobacco, diet, and 
exercise). There were three subscales to the scale: autono-
mous regulatory style (six questions), controlled regulatory 
style (six questions), and amotivation (three questions) with 
the autonomous regulatory style representing the most self-
determined form of motivation. Each subscale score ranged 
between 1 and 7.
Physicians’ support to motivate the patient was assessed 
by the HCCQ. HCCQ assesses the degree to which patients 
experienced their health care providers to be autonomy sup-
portive relative to controlling with respect to particular issues, 
behaviors, or treatments. HCCQ consists of five questions 
with a range from 0 to 6. The total HCCQ score varies from 
0 to 30 with higher values indicating greater patient percep-
tion of an autonomy supporting versus controlling approach 
from the health care providers.
health-related Qol
It was assumed that a high health-related QoL is linked to 
high treatment adherence as it has been used to measure 
drug efficacy.27,28 Health-related QoL was assessed after 6, 
12, 18, and 24 months in the study (Figure 1) by using the 
12-item short form questionnaire (SF-12) version 1.29 The 
SF-12 is a commonly used health-related QoL questionnaire, 
including 12 individual questions addressing the following 
eight domains: physical functioning, physical role, bodily 
pain, general health, vitality, social functioning, emotional 
role, and mental health scale. The questions were combined, 
scored, and weighted allowing for the generation of physical 
(physical functioning, role physical, bodily pain, and general 
health) and mental health (vitality, social functioning, role 
emotional, and mental health) summary scores ranging 
between 0 and 100, with 0 indicating the lowest level of 
health and 100 indicating the highest level.
The physical and mental component summary scores 
were compared with US norm-based scores, with scores .50 
indicating better health.30
safety
Safety was assessed descriptively and was based on the 
incidence and nature of adverse events (AEs), serious AEs 
(SAEs), and laboratory abnormalities (lymphocytes, alanine 
aminotransferase, and aspartate aminotransferase).
statistical methods
Study size calculation was based on previous studies showing 
an expected improvement in adherence after motivational 
interviews of 5% units with a standard deviation of 25%.31,32 
A total sample size of 230 patients was anticipated to have 
80% statistical power to detect this effect size with a 5% 
level of significance and accounting for an expected dropout 
rate of 15%.
The safety analysis set (SAS) consisted of all patients who 
received at least one dose of fingolimod after inclusion in the 
study and who had at least one safety or efficacy measure-
ment. The full analysis set (FAS) consisted of patients who 
were included in the safety set, who were diagnosed with 
RRMS, and who had at least one efficacy measurement at 
month 6. The per protocol set (PPS) consisted of patients who 
were included in the FAS and were deemed to have no major 
protocol violations that could interfere with the objectives 
of this study. Lack of adherence was not considered a major 
protocol deviation.
The primary efficacy endpoint was the mean treatment 
adherence (based on pill count) in the observational run-in 
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phase versus the motivational interview phase. The primary 
efficacy analysis was based on the PPS. The difference in 
adherence between the two phases of the study was ana-
lyzed by two-sided t-tests performed on the 5% level of 
significance.
The upper limit of treatment adherence was set to 
1 (100%); thus, adherence values above 1 were set to 1 in 
the statistical analyses. The secondary efficacy endpoints 
were mean TSQM-9, TSRQ, HCCQ, and SF-12 scores. The 
secondary efficacy analyses were based on the FAS. The 
secondary endpoints are presented with summary statistics 
for observed values.
Missing data were not imputed. Outliers were included in 
summary tables and were not handled separately. Available 
data from prematurely withdrawn patients were included in 
the analysis as far as possible.
Results
Patients
Between October 22, 2013, and April 30, 2014, a total of 
195 patients were recruited for the study. This sample size 
is somewhat lower than the number of anticipated patients 
based on the power calculations described above. However, 
this sample size would assure the detection of an adherence 
improvement of 6% with a statistical power of 80%–90% 
with a standard deviation of 25%.
Of the total number of patients recruited into the study, 
144 (73.8%) completed the study and 51 (26.2%) discon-
tinued the study (Figure 2). The two main reasons for dis-
continuation from the study were patients who discontinued 
upon own request (17 patients, 8.7%) and patients for whom 
treatment was stopped by the treating physician (16 patients, 
8.2% of which 7 [3.6%] were due to intolerance to treatment 
and 9 [4.6%] due to an AE).
The study population comprised 130 (66.7%) females 
and 65 (33.3%) males (Table 1). The mean age at the screen-
ing visit was 41 years. Majority of patients were Caucasian 
(99.5%). The mean duration of MS from diagnosis to 
informed consent was 7.46 years and the mean EDSS score 
at the screening visit was 2.99.
All the 195 enrolled patients were included in the SAS 
and thereby included in the analysis of safety and tolerability. 
•
•
•
•
•
Figure 2 Patient flow through the study.
Abbreviations: FAs, full analysis set; PPs, per protocol set.
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For the observational run-in phase, a total of 10 subjects were 
excluded from the FAS population due to no efficacy mea-
surements at month 6, resulting in an FAS of 185 patients. 
Of these patients, 59 had protocol deviations deemed to 
interfere with the study objectives leaving 126 subjects for 
the PPS. For the motivational phase, the FAS consisted of 
159 patients and the PPS 105 patients.
effect of motivational interview training 
of health care professionals – MiTi 
scoring
Results from the MITI scoring showed a high degree of MITI 
with high levels of motivational interviewing spirit, empathy, 
and behavior with no pronounced difference between before 
and after the motivational interview training of the health 
care professionals (Table 2).
Treatment adherence
The mean and median treatment adherence are summarized 
in Table 3 for both the phases of the study. In general, a very 
high treatment adherence was observed during the entire 
study with no statistically significant difference between the 
observational run-in phase (99%) and the motivational inter-
view phase (97%) (difference in adherence between phases 
was -0.0196 [-0.0453 to 0.0061]
95% CI
, p=0.1329).
Treatment satisfaction
High TSQM-9 scores were observed already at baseline, and 
they remained high for the entire duration of the study across 
all TSQM domains with no noteworthy difference between 
the two phases of the study (Figure 3). The highest satisfac-
tion scores were seen for the convenience domain (ranging 
from 94.51 to 95.78).
Treatment motivation
The degree to which patients tended to take their medication 
in an autonomous (self-determined), controlled regulatory or 
amotivation style is depicted in Figure 4. The data showed 
that the patients tended to have a more self-determined form 
of motivation for taking their treatment compared to a con-
trolled or amotivation form throughout the study.
The mean total HCCQ score was generally high during 
the study with no pronounced difference between the two 
phases of the study ranging between 26.33 at baseline and 
27.69 at month 24 (visit 5) (Figure 5). Thus, the patients 
generally had a perception of their health care providers 
providing an autonomy support.
Table 1 Patient demographics and baseline characteristics
Characteristics Enrolled patients
N=195
Age, years
number of observations
Mean (sD)
Median
Min – max
195
41 (8.66)
42
19–60
Sex, N (%)
Female
Male
130 (66.7%)
65 (33.3%)
Race, N (%)
caucasian
Other: mix white/native American
194 (99.5%)
1 (0.5%)
Duration of MS, years
number of observations
Mean (sD)
Median
Min – max
195
8.97 (6.00)
7.46
1.0–30.6
EDSS score
number of observations
Mean (sD)
Median
Min – max
191
2.99 (1.71)
2.50
0.0–7.0
Abbreviations: eDss, expanded disability status scale; max, maximum; min, 
minimum; Ms, multiple sclerosis; n, number of patients.
Table 2 results of motivational interviewing treatment integrity 
coding
Global rating
spirit (partnership, evocation, 
autonomy)
Pre-training 3.4 small 
improvementPost-training 3.8
empathy Pre-training 3.6 small 
improvementPost-training 3.7
Behavior rating
Reflection to question 
ratio (r:Q)
Pre-training 0.47:1 no improvement
Post-training 0.51:1
Percentage of open 
questions (%)
Pre-training 22% improvement
Post-training 28%
Percentage of complex 
reflections (%)
Pre-training 54% small 
improvementPost-training 57%
Percentage of motivational 
interview assessment, MiA (%)
Pre-training 56% improvement
Post-training 67%
Table 3 Treatment adherence
Study phase Adherence
Observational run-in phase
number of observations
Mean (sD)
Median
Min – max
126
0.99 (0.07)
0.99
0.76–1.50
Motivational interview phase
number of observations
Mean (sD)
Median
Min – max
105
0.97 (0.12)
0.99
0.20–1.42
Abbreviations: min, minimum; max, maximum.
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Figure 3 Treatment satisfaction by TsQM-9 domain.
Notes: TsQM-9 scores were calculated based on the FAs (n=185). The scores can range between 0 and 100. The number of observations at different visits was: visit 1 =181, 
visit 2 =181, visit 3 =164, visit 4 =153, and visit 5 =137.
Abbreviations: TsQM-9, Treatment satisfaction Questionnaire for Medication 9; FAs, full analysis set.
Figure 4 Treatment self-regulation.
Notes: TsrQ scores were calculated based on the FAs (n=185). The scores can range between 1 and 7. The number of observations at different visits was: visit 1 =192, 
visit 2 =184, visit 3 =168, visit 4 =156, and visit 5 =138.
Abbreviations: TsrQ, Treatment self-regulation Questionnaire; FAs, full analysis set.
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Figure 5 Total hccQ score.
Notes: hccQ scores were calculated based on the FAs (n=185). The total hccQ scores can range between 0 and 30. The number of observations at different visits was: 
visit 1 =182, visit 2 =184, visit 3 =168, visit 4 =157, and visit 5 =137.
Abbreviations: hccQ, health-care climate Questionnaire; FAs, full analysis set.
health-related Qol
The mean SF-12 physical component summary score 
remained fairly constant throughout the study varying around 
a value of 45 (range: 44.49–45.91) (Figure 6). Likewise, the 
mean SF-12 mental component summary score also remained 
within the same level throughout the study varying around a 
value of ~50 (range: 49.79–51.26).
Both the physical and mental component summary scores 
were a little lower, yet comparable, than the average for the 
general population in the United States.
safety
Overall, treatment with fingolimod was well tolerated, and 
the observed AEs were consistent with what has previously 
been reported with fingolimod.
A total of 116 of 195 patients (59.5%) reported 228 AEs 
during the study and 46 of the patients (23.6%) reported AEs 
considered related to the treatment. Of all the patients, 11 
patients (5.6%) discontinued treatment due to 12 AEs. The 
most frequently reported AEs were within the system organ 
class “infections and infestations” with 64 of the patients 
(32.8%) reporting such events, and with pneumonia, cystitis, 
and influenza representing the most frequently reported pre-
ferred terms. A total of 14 patients (7.2%) reported 19 SAEs 
of which four were considered as related to the treatment 
(breast cancer, intentional overdose, malignant melanoma, 
and neoplasm). No deaths were reported during the study, 
and there were no clinically significant findings from safety 
laboratory assessments.
Discussion
Poor adherence to long-term therapy is a well-known problem 
in MS.7 Since adherence is imperative for treatment outcome, 
it is important to consider and evaluate adherence as well 
as factors related to adherence to a particular medication 
to assure that therapeutic goals are achieved, to minimize 
negative impacts of disease activity on RRMS patients 
and to reduce unnecessary costs on society to treat disease 
exacerbations.
Published data on treatment adherence with fingoli-
mod are limited. Therefore, the present study investigated 
treatment adherence as well as parameters closely related 
to adherence, that is, treatment satisfaction, motivation, 
and health-related QoL, in RRMS patients treated with 
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fingolimod in Denmark. In addition, since motivational inter-
views have previously shown to increase patients’ adherence 
to treatment,15 the effect of a motivational interview support 
program on these measures was also evaluated.
The results demonstrated a very high level of adherence to 
fingolimod treatment during the entire study with no statisti-
cally significant difference between the observational run-in 
phase (99%) and the motivational interview phase (97%). 
These adherence levels are somewhat higher than levels 
published for other types of DMTs in MS which have been 
reported to range from as low as 28% up to 88%.8 Generally, 
the adherence to fingolimod treatment has been higher than 
other oral DMTs for MS.33,34 In addition, the adherence 
levels found here are also higher than the levels found for the 
minority populations of Hispanic and African American MS 
patients treated with fingolimod.35 In this regard, it should 
be emphasized that the study includes a limited number of 
patients and concerns only MS patients treated in Danish MS 
clinics, and there may be significant differences to other MS 
clinics with fewer resources to treat these patients.
The results presented here should be considered within 
the context of an observational, open-label, non-randomized 
study design, in which the patients were drawn from 8 of 
10 possible Danish MS clinics. Participants agreeing to 
participate may tend to score higher on patient-reported 
outcomes (PROs) and be more adherent compared to a more 
general MS population. The discontinuation rate was 26.2% 
during the 24 months which limit longitudinal interpreta-
tions of the study; however, this discontinuation rate should 
be expected based on experiences from the Phase III study 
program where 19%36 to 32%37 was seen (both studies were 
24 months studies).
The primary endpoint was adherence as measured by pill 
count. Thus, patient’s medication was counted at every visit 
to the clinic. In turn, there is an inherent risk of incomplete 
return of unused fingolimod as well as fingolimod capsules 
that were lost and thus never taken. Some patients may have 
difficulties explaining how and why they lost these rather 
expensive capsules and have a desire to appear adherent in 
the eyes of their doctor. Thus, potential social desirability 
bias of the patients may have led to an overestimation of 
adherence.
In accordance with the high adherence levels, a high 
treatment satisfaction with fingolimod, reflected by high 
Figure 6 sF-12 physical and mental component summary scores.
Notes: Physical and mental component summary scores were calculated based on the FAs (n=185). sF-12 component scores can range between 0 and 100. The number of 
observations at different visits was: visit 1 =173, visit 2 =162, visit 3 =152, visit 4 =145, and visit 5 =127.
Abbreviations: sF-12, 12-item short form questionnaire; FAs, full analysis set.
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TSQM-9 scores, was observed throughout the study with 
the highest TSQM-9 scores seen for the convenience domain 
(ranging from 94.51 to 95.78). Furthermore, high mean SF-12 
physical and mental component summary scores, comparable 
to those for the general population in the United States,30 were 
observed throughout the study indicating a high self-reported 
health-related QoL of the fingolimod-treated patients. 
In addition, results from the TSRQ and HCCQ indicated that 
patients were predominantly self-determined (as compared 
to being controlled) in their form of motivation for taking 
their medication and that they mainly felt that their health 
care provider used an autonomy supportive approach when 
meeting them. In this regard, it has previously been observed 
that patients treated with fingolimod have significant 
improvements in several self-reported outcomes compared to 
patients who continue injectable DMTs, including QoL and 
TSQM.38 Thus, the high baseline adherence levels observed 
in this study could be partly explained by a high satisfaction 
with fingolimod as well as a high treatment motivation and 
QoL of the included patients. As satisfaction, motivation, 
and QoL remained high throughout the study, this in part 
explains high adherence.
It should be mentioned that one of the inclusion criteria 
for this study was that patients were required to having 
received fingolimod for a minimum of 6 months prior to 
inclusion. This was introduced to avoid misinterpretation 
of adherence due to, for example, low tolerance leading to 
change of treatment or high adherence during the first treat-
ment period. However, this inclusion criteria may also have 
introduced some selection bias, since only stable, well-treated 
patients were selected for the study, which could potentially 
have led to an overestimation of the assessed PROs.
An additional purpose of the study was to investigate the 
effect of a motivational interview support program on treat-
ment adherence. Motivational interviews have previously 
been shown to have a positive effect on treatment adherence 
in MS,39 and it was thus highly relevant to investigate whether 
this could promote adherence in this patient population as 
well. However, the results showed no pronounced effect of 
a motivational interview on any of the parameters investi-
gated, which is probably the result of these measures being 
high already at baseline leaving no room for improvements. 
Accordingly, results from the MITI scoring showed that the 
health care professionals were highly skilled in motivational 
interviewing already before the motivational interview 
training, thus probably partly explaining the lack of effect 
on adherence.
These data could suggest that Danish MS patients 
have a high degree of support in the health care system 
providing help to cope with their chronic disease which 
partly could explain their high adherence as observed in the 
present study.
Regarding safety, treatment with fingolimod was found 
to be well tolerated and no new and unexpected safety signs 
were reported.
Conclusion
This 24-month open-label study demonstrated high levels 
of treatment adherence as well as treatment satisfaction, 
motivation, and health-related QoL in a Danish cohort of 
RRMS patients treated with fingolimod. Due to the high 
level of treatment adherence already from baseline, no 
effects of a motivational interview support program could 
be demonstrated.
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